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Abstract
Recent developments in the statistical analysis of genome-wide studies are reviewed. Genome-wide analyses are becoming increasingly
common in areas such as scans for disease-associated markers and gene expression proﬁling. The data generated by these studies present
new problems for statistical analysis, owing to the large number of hypothesis tests, comparatively small sample size and modest
number of true gene effects. In this review, strategies are described for optimising the genotyping cost by discarding promising genes at an
earlier stage, saving resources for the genes that show a trend of association. In addition, there is a review of new methods of analysis
that combine evidence across genes to increase sensitivity to multiple true associations in the presence of many non-associated genes.
Some methods achieve this by including only the most signiﬁcant results, whereas others model the overall distribution of results as a
mixture of distributions from true and null effects. Because genes are correlated even when having no effect, permutation testing is often
necessary to estimate the overall signiﬁcance, but this can be very time consuming. Efﬁciency can be improved by ﬁtting a parametric
distribution to permutation replicates, which can be re-used in subsequent analyses. Methods are also available to generate random draws
from the permutation distribution. The review also includes discussion of new error measures that give a more reasonable interpretation
of genome-wide studies, together with improved sensitivity. The false discovery rate allows a controlled proportion of positive results
to be false, while detecting more true positives; and the local false discovery rate and false-positive report probability give clarity on whether
or not a statistically signiﬁcant test represents a real discovery.
Keywords: genome scan, genetic association, multiple testing, permutation test, false discovery rate
Introduction
Recent technological advances allow the rapid generation of
vast quantities of molecular biological data.
1,2
At the same
time, the sequencing of the human genome and subsequent
efforts to catalogue the variation within it
3
have created
opportunities for testing thousands of sequence variations for
association with disease, behavioural traits and physiological
markers. Such applications are appealing because of the relative
lack of success, to date, of positional cloning strategies that
start with family-based linkage mapping,
4
most likely due to
insufﬁcient sample sizes to detect genes of modest effect.
5
The whole-genome association scan is an increasingly feasible
study design in which the genotyped markers are sufﬁciently
closely spaced to detect linkage disequilibrium (LD) with
all aetiological variants, and well-powered sample sizes are
more attainable.
6
Some initial studies have been performed in
special populations
7,8
and in small samples of outbred popu-
lations;
9,10
genome-wide admixture scans are imminent
11,12
and, ultimately, routine scans will be performed for common
diseases in large cohorts of outbred populations.
13
Array experiments measuring large numbers of transcrip-
tion or expression levels are another form of genome-wide
analysis that have become widespread.
14
Although the effect
sizes expected in these studies are large by comparison with
disease association studies, the sample sizes are constrained by
cost to be relatively small, so that both types of study
encounter problems of statistical power (Table 1). Expression
levels can be regarded as quantitative traits under genetic
control, so that both kinds of large-scale exploration can
occur in genome scans for loci inﬂuencing expression levels,
15
or phenome scans demarking the inﬂuence of genetic
pathways.
16,17
The analysis of large exploratory studies creates new pro-
blems for methodology and interpretation. Primarily, there is
the multiple testing problem, whereby the chance of an
exceptional result increases with the number of tests per-
formed, even when there is no true association. To alleviate
this problem, two broad strategies have emerged: ﬁrst, to
devise more sensitive tests, so that the penalty for multiple
testing is less severe; and, secondly, to propose different
measures of experimental error for which the interpretation of
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multiple testing is less serious. Furthermore, genome-wide
analysis creates problems of computational and cost efﬁciencies
on account of the large volume of data to be generated and
analysed.
Here, some recent work addressing these problems is
reviewed. For the study design, work is summarised that
minimises the cost of a study, while maintaining its power. For
the analysis, methods are reviewed for improving sensitivity
in the presence of multiple gene effects, by combining
evidence across tests, and some methods for reducing the
computational burden of permutation tests are discussed. The
review concludes with a discussion of alternative error
measures including false discovery rates.
This review is mainly concerned with a whole-genome
association scan, using single nucleotide polymorphisms
(SNPs), for a dichotomous disease status. It will be clear,
however, that many of the methods apply in other situations,
in particular to array expression studies. Although there are
important differences between these two applications —
including the number of expected true associations, sample
size and effect size (Table 1) — their common exploratory
character suggests that further advances may arise from cross-
application of ideas between these areas. For this reason, some
methods developed for expression studies are reviewed; there
is also a discussion on whether they may be suitable for genetic
association scans. The objects of inference used will be
‘genes’
18
, with the understanding that, in this context, this can
mean SNPs, whole genes, haplotype blocks, transcript levels
or other features.
Study design
Large samples of unrelated individuals have become the design
of choice for genome-wide association scans, because earlier
concerns about population stratiﬁcation have been largely
allayed by empirical methods.
19
Estimates of the total sample
size are in the order of thousands.
20
Because the majority
of genes are not associated with disease, it is uneconomical
to genotype the whole sample for all genes. Sequential study
designs, in particular a two-stage block design, have been
proposed for reducing the total cost of a genome-wide
experiment, which remains the main limiting factor prevent-
ing large-scale application. In a two-stage design, all of the
genes are typed in a subset of the sample, with only the genes
showing a trend of association being taken forward for geno-
typing in the remainder. This directs resources towards true
associations at an earlier stage, so that the available sample
size is larger for genes with true effects.
The design parameters for a two-stage study include the
total cost, total sample size, size of the ﬁrst and second
sub-samples and rejection criterion at the end of the ﬁrst
stage. Studies with only two stages are considered, although
more could be performed. Some of these parameters are
constrained in advance, with the others then chosen to
optimise some objective. One approach is to consider the
genotyping cost as ﬁxed and then ﬁnd parameters that give the
most power.
21,22
A general rule of thumb, considering a
number of disease models and correlation structures between
markers, is to allocate 75 per cent of resources to the ﬁrst
stage and then carry the most promising 10 per cent of
markers to the second.
22
Here, the sample size is a function
of the genotype unit cost and the number of markers,
within the overall cost constraint.
It is more likely that the sample size is ﬁxed (say, to provide
sufﬁcient power to detect a single association) and the goal
is to minimise costs while achieving power close to that of
the one-stage design.
23
In many situations, the cost can be
halved while keeping power within 1 per cent of the one-stage
design; thus, the total sample size can be calculated to achieve
a certain power (say 81 per cent) in the one-stage design and
parameters then optimised for a two-stage design. Considering
a range of genetic models, a general guideline is to set the
sample size of the ﬁrst stage to have 97 per cent power for
individual tests and carry forward all markers with nominal
p-values less than 0.15. The sample size for the ﬁrst stage
cannot be calculated without knowledge of the true effects,
however, so a more practical approach is to consider the ranks
of test statistics of the true effects.
24
Here, it is shown that
similar information to the one-stage design is obtained by
genotyping all markers on 50 per cent of the sample and then
genotyping the 10 per cent most promising on the remainder,
resulting in a decrease of about 45 per cent in the number of
genotypes. Again, the total sample size can be calculated for a
one-stage design; this last guideline is currently the most
practical available and applies over a wide range of genetic
models and correlation structures between markers.
Table 1. Determinants of power in genome-wide association and expression studies.
Genetic association study Gene expression study
Number of genes tested High High
Number k of true effects Few; 1 , k , 50 Moderate; k ..1
Sample size Large; thousands Small; tens
Gene effect size Low; odds ratio ,2 High; log fold-change .2
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An application of this strategy has been reported in
which the primary constraint is the quantity of DNA available
for study subjects.
25
About 44 per cent of the sample had
sufﬁcient DNA to be typed for all markers, with the
remaining 56 per cent used for the second stage. An important
feature of this study is that the test statistics are calculated over
the full sample, with adjustment made for the interim test.
This is in contrast to the simpler approach used in the
simulation studies,
21,23
in which test statistics were calculated
separately for the two stages and their p-values combined
into an overall signiﬁcance. Analysing both stages at once
25
makes more efﬁcient use of information and will be the
more powerful method for computing signiﬁcance in the
whole sample.
Formal sequential designs have also been proposed for
genetic association studies.
26
These can result in substantial
cost savings, on average, but have yet to become widely
adopted, owing mainly to logistical difﬁculties. For example,
the stopping criteria must be applied to each gene separately,
but genotypes are often obtained in bulk in array format,
which makes it difﬁcult to apply sequential designs efﬁciently
across many genes. The two-stage designs are a compromise
solution using frequentist inference, which also avoid the
uncertainty in actual sample size that occurs with sequential
inference. Future studies may introduce further design
variables. For example, different genotyping technologies may
be used in the two stages, with different unit costs, perhaps
using DNA pooling.
27
Optimal study designs can be derived
for these conditions following current principles.
Analysis methods for multiple
associations
Many analysis methods are available for genetic data, but a ﬁrst
pass through a genome-wide scan may normally consist
of single-locus tests for trend, perhaps additionally with
two-locus interaction tests.
28
Several methods are now
available that exploit the important feature that the majority of
tested genes are not associated, but there are a small number of
true, but weak, associations to be found. These methods are
useful both for establishing statistical signiﬁcance more strongly
than single-locus tests, and for informally suggesting sets of
genes for follow-up study.
In the traditional hypothesis-testing framework, each gene
is tested individually and then a stepwise adjustment procedure
is applied both to control the family-wise type-1 error rate
(FWER) and to declare individual genes associated.
29
This
approach, related to the Bonferroni correction, achieves strong
control of the FWER, which is the probability of at least one
false positive being within the desired rate when there are
any number of true positives. This is generally considered to
be too conservative for genome-wide studies, however,
because we can tolerate a small number of false positives if
most true positives are detected. More preferable is weak
control of FWER, which ensures that the probability of at
least one false positive is within the desired rate only when
there are no true positives. This is desirable, because we must
defend against the possibility of there being no true associ-
ations in the sample, but it allows us to tolerate some false
positives if some true positives are present.
A joint test of multiple genes can maintain weak control of
FWER and should reveal greater evidence for association
from a set of genes, although perhaps with less speciﬁcity for
individual genes. This argument motivates the partial sum
statistics,
30
which are formed by obtaining test statistics (typi-
cally x
2
tests from a contingency table) for each individual
gene and then forming the sum of the K largest statistics,
where K is a ﬁxed number called the length. The signiﬁcance
of the sum can be assessed by a permutation test and an overall
signiﬁcance estimated over a range of lengths.
A more ﬂexible alternative to the sum statistic is the trun-
cated product of p-values. Here, the product is formed of all
the p-values lower than a preset threshold,
31
or the K smallest
p-values.
32
When the individual tests have the same distri-
bution, the rank truncated product has equivalent power to
the sum statistic, but is more balanced when the tests have
different distributions. This will occur, for example, when
conducting haplotype-based tests on regions of different sizes,
leading to tests with different degrees of freedom. Analytic
distributions are known for independent tests, which have
been used in simulation studies to show improved power
for combined evidence methods compared with traditional
corrections.
31,32
The present authors prefer the truncated
product to the sum statistic on account of its balanced com-
bination of different test, and also prefer to truncate on rank
rather than threshold because the number of true gene effects
is ﬁxed across studies, whereas their p-values are random.
32
The length K should be close to the actual number of true
associations, but this is generally unknown. A range of lengths
could be tested, with the most signiﬁcant length used to select
genes for follow-up analysis; but there is no formal basis for
this strategy, and simulation studies show that it is capable of
grossly over- or under-estimating the number of true associ-
ations.
33
A judicious choice of a ﬁxed length, say K , 20 for a
genome-wide association scan, is generally advisable provided
that the tests are reasonably independent. When there is strong
dependency between tests, such as in single-marker analysis
of a dense genome-wide scan, then the variable-length
approach can be used to establish statistical signiﬁcance, but
not to estimate the number of follow-up genes. Informally,
genes would be followed up in rank order of signiﬁcance;
and if the prior power is high, this will tend to identify the
true associations.
32
In fact, formal adjustments based on the
closure principle are available for individual tests, which allow
strong control of FWER,
34
but the primary use of truncated
products is to show that the strongest associations indeed
arise from true effects.
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In working with the summary p-value rather than the
complete data, some information is lost, and a single analysis
of the data may be more efﬁcient. A natural approach is to
estimate all gene effects together in regression model. On the
genome-wide scale, a ﬁxed-effects regression is impractical,
requiring estimation of many more parameters than there
are observations. Therefore, several methods proposed for
microarrays regard a gene as having a random effect, and
model the distribution of gene effects by parametric forms that
can be estimated. A simple model is to assume a normally
distributed effect around zero,
35
although this may lack power
when most genes have no effect. The model can be extended
by assuming that the effect variability comes from small and
stronger effects, with inference based only on the stronger
effects.
36
Another alternative is a mixture of a zero-centred
normal and a point mass at zero
37
or, more generally, a mix-
ture of three normals with respectively positive, zero and
negative means.
38
Here, the zero-centred distribution is
regarded as the null distribution, which allows for small non-
zero effects to be regarded as uninteresting if there is sufﬁcient
evidence for stronger effects.
These approaches reduce the dimensionality of the infer-
ence while modelling the complete data, rather than sum-
marising each gene before combining evidence. These
methods offer promise for genome-wide association scans, an
important open question being the precision in estimating the
random effects distribution when the number and size of
true associations are small. For example, a method for testing
whether the overall distribution of p-values is uniform
39
has
very little power compared with the Bonferroni correction
when the number of true effects is small (authors’ unpublished
data). Another important issue is the choice of random effects
distribution: current methods assume hierarchical or mixture
normal distributions, but experimental geneticists have
favoured gamma distributions.
40,41
A useful feature of the
mixture distribution models is that they generate maximum-
likelihood probabilities of membership to each of the mixture
components, for each gene, which can be interpreted
informally as posterior probabilities of association allowing
individual genes to be selected for follow-up study.
Permutation testing
When the assumptions underlying analytical distributions are
not met, permutation tests are a popular method for com-
puting signiﬁcance levels. In a genome-wide association study,
the problem is that genotypes are correlated due to LD;
indeed, the correlations are necessary for the design to be
successful. The standard procedure is to reassign trait values
among study subjects, while keeping their genotypes ﬁxed,
thereby preserving the correlation structure across the multiple
genes and realising the exchangeability conditions for a valid
test.
42
When performing thousands of tests on thousands of
subjects, however, a permutation procedure using thousands of
replicates becomes extremely time-consuming, with possible
running times of days or weeks. Therefore, more efﬁcient
approaches to permutation testing have recently been
proposed.
The accuracy of the permutation test can be improved by
noting that the minimum p-value, sum statistic and truncated
product can all be regarded as the extreme value of a large
number of observations.
33
Therefore, they should follow the
extreme value distribution
43
and by ﬁtting the parameters
of the distribution to the values observed in permutation
replicates, more accurate signiﬁcance levels are obtained.
Equivalently, fewer replicates are needed to reach a given
accuracy. The efﬁciency gain depends upon a number of
factors, including the true signiﬁcance level and the number of
tests, and it is difﬁcult to compute standard errors for the
empirical p-values. Nevertheless, this approach has the
advantage of being generally applicable and, importantly, the
ﬁtted distribution can be re-used in subsequent tests of the
same genes in the same population. This will be useful for
studies based on a standard genome-wide marker panel,
3
leading to substantial time savings over the long term.
A complementary approach is to reduce the computation
within each replicate. Lin
44
considered score statistics from
regression models, showing that it is sufﬁcient to multiply
the score contributions of each subject by a normal random
deviate to generate a realisation from the null distribution.
Alternatively, Seaman and Mu
¨
ller-Mysock
45
suggest sampling
directly from the multivariate distribution for all the genes.
The distribution can be estimated by considering the score test
from a regression model that includes all the genes as predic-
tors. This estimation may be difﬁcult when the number of
genes exceeds the number of subjects for which the procedure
may need to be applied piecewise to subsets of genes. The
approach of Lin also requires the sample size to exceed the
number of genes, but preliminary results suggest that it would
be more robust than that of Seaman and Mu
¨
ller-Mysock when
applied across the whole genome.
44
Both of these approaches
require the analysis to be expressed as a score statistic from
a regression model, which can be done in most situations
but may require additional work by the user. Currently, Lin’s
method seems better suited to genome-wide analysis, whereas
that of Seaman and Mu
¨
ller-Mysock is more applicable and
efﬁcient in smaller-scale candidate gene studies.
46
A further approach is to assume that the sampled markers
are representative of an ‘effective number’ of independent
tests.
47–50
After estimating this number — for example, from
the singular-valued decomposition of the genotype correlation
matrix
50
— asymptotic formulae can be applied. There is
no formal basis for this approach, however, and studies based
on real data indicate that the results are not always accurate;
51
indeed, there may be no such effective number after all.
33
This approach is not recommended; however, if it is used, all
signiﬁcant results should be conﬁrmed by a permutation test.
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False discovery rates
Another perspective on the multiple testing problem is that
the family-wise error rate is not the most appropriate
measure, and that other measures should be used that have
better sensitivity and speciﬁcity in genome-wide studies.
Although weak control of FWER for the overall signiﬁcance
has been advocated, some error control for the single tests is
also desirable. Here, two prominent alternatives are discussed:
false discovery rates (FDRs)
52,53
and posterior error rates.
54,55
The original FDR by Benjamini and Hochberg
52
is the
expected proportion of false positives among all positive
results, with the proportion deﬁned as zero if there are no
positives. That is, if R is the number of positive results in a
study and V is the number of these that are false — that is, do
not arise from true gene effects — then:
FDR ¼ EðV=RjR . 0ÞPrðR . 0Þ:
Subsequently, Storey and colleagues
53,56
have argued that
the choice of the appropriate rate depends on how many
positive results there are, and, furthermore, that the rate is only
meaningful when there is at least one positive. This motivates
the positive FDR (pFDR), deﬁned as the expected proportion
of false positives among all positive results, conditional on
at least one positive at a given signiﬁcance level:
56
pFDR ¼ EðV=RjR . 0Þ:
Rather than setting a ﬁxed pFDR rate to control, Storey
and colleagues suggest giving a value to each test that indicates
what pFDR would result from declaring that test signiﬁcant.
The follow-up tests can then be chosen based on joint con-
sideration of the number of tests selected and the pFDR
associated with them. Formally, the q-value associated with an
individual test is deﬁned as the minimum pFDR achieved
when declaring all tests signiﬁcant at the level of the test’s p-
value. A q-value can be estimated for each test in a genome-
wide experiment and follow-up tests selected from those with
the lowest q-values. This last stage is somewhat informal and
may be driven by logistic and ﬁnancial constraints.
A difﬁculty with FDR methods is that they control an
expected proportion, whereas an investigator will be more
concerned with the actual proportion of false positives
within a study. Some insight is gained by considering the
variation in within-study false discovery proportion or false
discovery variance. Let i be an integer with p
(i)
the i-th
smallest p-value from a set of m tests. If the i most signiﬁ-
cant tests are declared positive, then mp
(i)
estimates the
maximum number of false positives. The associated variance
is mp
(i)
(1 2 p
(i)
) (because the truth of a positive test is a
binomial outcome) and the coefﬁcient of variation is
ﬃﬃﬃﬃﬃﬃﬃﬃ
12p
ðiÞ
p
ðiÞ
q
for the within-study false discovery proportion. This is
greatest when p
(i)
is small, so, for a ﬁxed set of p-values, this
coefﬁcient of variation is greatest when the fewest tests are
declared signiﬁcant. This will occur when a low error rate is
set, or when there are few true associations, or when the
power is low. In genome-wide association scans, the number
of true associations is expected to be small by comparison
with the number of tests, so that the false discovery
variance is relatively high in relation to the target rate,
and the FDR approach may not be reliable for controlling
the error rate within studies. In gene expression exper-
iments, however, the number of true associations is
somewhat higher and FDR methods are more appropriate
for those studies.
Korn et al. study the within-study proportion of false
discoveries and give procedures that keep the number (or
proportion) of false discoveries within an upper bound with
given probability.
57
The attraction of this approach is that
one can limit the number of false positives with reasonable
conﬁdence, with the main disadvantage being increased
computation. It is uncertain how the false discovery
proportion behaves when it falls outside the upper bound and,
although this approach is attractive, further operating
characteristics may be needed before it becomes more
widely used.
A further difﬁculty with FDR is that it says little about
the individual tests. The most signiﬁcant tests are most likely
to be the true positives, but FDR and q-values ignore this in
favour of averaging the error rate across all signiﬁcant tests.
Efron and colleagues
58,59
propose the local FDR as the
posterior probability that a null hypothesis is true, given
an observed statistic. The local FDR is calculated as
p
0
f
0
ðT Þ
p
0
f
0
ðT Þ þ ð12 p
0
Þf
1
ðT Þ
;
where p
0
is the prior probability that the null hypothesis is
true, T is a test statistic and f
0
and f
1
are the probability
densities of T under the null and alternative hypotheses,
respectively. p
0
and f
1
may be unknown but could be esti-
mated from the data.
58,60,61
Note, however, that when the
true value of p
0
is near one, as is likely in disease association
scans, empirical estimates of p
0
may be greater than one,
which leads to a downward bias if these estimates are
truncated at one. Thus, it is better to ﬁx a prior estimate of
p
0
from genomic considerations such as the number
of expected disease genes (O(10
1
)) and the number of genes
in the genome (O(10
4
)).
62
Both the local FDR and the q-value are calculated for
individual tests. The q-value should be preferred if all positive
tests will be followed up with roughly equal priority, which
may be the case for a moderately powered study in which true
and false positives are not well separated. The local FDR is
preferable if decisions to follow up positive tests are taken on a
case by case basis, because it is a property of single tests rather
than the whole set of positive tests. This applies if there are
a few very strong associations, together with some moderate
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ones, or if additional sources of evidence, such as biological
plausibility, are taken into account, together with the statistical
association.
A related quantity is the false-positive report probability
(FPRP).
55,63
This is the posterior probability that a null
hypothesis is true, given a statistic at least as extreme as that
observed. It is calculated as
p
0
F
0
ðT Þ
p
0
F
0
ðT Þ þ ð12 p
0
ÞF
1
ðT Þ
where now F
0
and F
1
are the cumulative distributions. For
known p
0
and F
1
and large number of multiple tests, the
FPRP is the same as the q-value,
56
the main difference being
one of context. FPRP is intended to be applied across multiple
studies and calculated from prior models, whereas q-values are
motivated by the within-study FDR and are usually estimated
from data. FPRP is also mathematically complementary to the
positive predictive value of a discriminant,
64
again differing in
context. Because FPRP is a property of a range of test stat-
istics, it is appropriate for setting guidelines for the reporting
of signiﬁcant results, based on assumed models for p
0
and F
1
.
This means that results can continue to be reported according
to their p-values, but with modiﬁed thresholds of signiﬁcance.
A known proportion of reported results will then be false;
however, for assessment of speciﬁc tests for follow-up, the local
FDR is more relevant to investigators.
Posterior error rates such as local FDR and FPRP are
gaining support because informed proposals can now be made
for the prior probability of the null being true, based on
genomic considerations.
55,62
Which of the various measures to
use depends on the context. Some of the determining factors
are summarised in Table 2.
Concluding remarks
Several aspects of the analysis of genome-wide studies have
been discussed, including study design, analysis method and
error control, all of which bear on the likelihood of
successfully identifying gene effects. There are some key
aspects that have not been considered here, including
selection and grouping of markers to be tested, population
choice and data quality control. To some extent, these issues
are speciﬁc to the type of study; this review has focused
on the more general statistical issues that apply to most
studies.
The ﬁeld will continue to develop rapidly as more
studies are completed and there is much scope for new
methodology. In particular, combinations of the current
methods may prove to be fruitful — for example,
including combined evidence tests within a two-stage
design. There is no best method for all studies, because
of their differing properties and aims, but this review has
identiﬁed some of the questions that should guide the
choice of analysis method. Another important area for
development, which has not been discussed here, will be
the incorporation of evidence from several sources,
including association studies, gene ontology annotation,
information from model organisms and structural bio-
informatics, to give a holistic appraisal of the effects of
genetic variation.
Table 2. Comparison of different error rates and analysis methods. ‘Error control’ indicates whether a method provides some measure
of error: (1) type-I error; (2) posterior probability of association; (3) expected proportion of false discoveries in a series of tests. ‘Appro-
priate for’ indicates whether, in the view of the authors, a method is suitable for genome-wide association or expression studies, based on
the factors in Table 1.
Error control for Appropriate for
Whole study Single test Association study Expression study
Family wise error, strong Yes (1) Yes (1) No No
Family wise error, weak Yes (1) No Yes Yes
Minimum p-value Yes (1) Yes (1) Somewhat No
Truncated p-value product Yes (1) No Yes Possibly
Random gene effects model Yes (1) Yes (2) Possibly Yes
False discovery rate Yes (3) No No Yes
Q-value Yes (3) Some (3) No Yes
Local false discovery rate Yes (2) Yes (2) Yes Yes
False-positive report probability Yes (3) Some (3) Yes Yes
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